
WHAT IS CLAIMED IS:

[Claim 1]. A crystalline form of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I):



selected from the group consisting of:

anhydrate Form B of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I);

anhydrate Form A of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I);

anhydrate Form C of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I);

anhydrate Form F of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I);

anhydrate Form J of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I);

anhydrate Form L of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I);

THF solvate Form H of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I, THF solvate);


AcOH solvate Form K of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I, AcOH solvate);

dioxane solvate Form M of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I, dioxane solvate);

acetone solvate Form Q of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I, acetone solvate); and

methanol solvate Form R of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I, methanol solvate).

[Claim 2~~2~~]. A crystalline anhydrate form of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I):



characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at 16.7, 17.0, 17.3, 17.7, 19.0, 19.6, or 23.6° 2θ ± 0.2° 2θ, Form B.

[Claim 3~~3~~]. The crystalline form of claim 2~~2~~, characterized by an XRPD pattern comprising four or more peaks at 16.7, 17.0, 17.3, 17.7, 19.0, 19.6, or 23.6° 2θ ± 0.2° 2θ.

[Claim 4~~4~~]. The crystalline form of claims 2~~2~~ or 3~~3~~, characterized by an XRPD pattern comprising five or more peaks at 16.7, 17.0, 17.3, 17.7, 19.0, 19.6, or 23.6° 2θ ± 0.2° 2θ.

[Claim 5~~5~~]. The crystalline form of any one of claims 2~~2~~ to 4~~4~~, characterized by an XRPD pattern comprising peaks at 16.7, 17.0, 17.3, 17.7, 19.0, 19.6, and 23.6° 2θ ± 0.2° 2θ.


[Claim 6~~6~~]. The crystalline form of any one of claims 2~~2~~ to 5~~5~~, characterized by an XRPD pattern comprising peaks at 9.8, 10.4, 11.2, 11.8, 13.4, 13.7, 14.8, 15.8, 16.2, 16.6, 16.7, 17.0, 17.3, 17.7, 18.0, 19.0, 19.6, 20.3, 20.5, 20.8, 21.0, 21.3, 22.0, 22.3, 22.7, 23.6, 23.8, 24.4, 25.4, 25.6, 25.7, 26.3, 28.1, 28.7, and 37.2° 2θ ± 0.2° 2θ.

[Claim 7~~7~~]. The crystalline form of any one of claims 2~~2~~ to 6~~6~~, characterized by an XRPD pattern substantially as shown in **Error! Reference source not found.**~~FIG. 1~~.

[Claim 8~~8~~]. The crystalline form of any one of claims 2~~2~~ to 7~~7~~, characterized by a differential scanning calorimetry (DSC) thermogram having at least one endotherm with an onset of about 255°C.

[Claim 9]. The crystalline form of any one of claims 2~~2~~ to 8~~8~~, characterized by a DSC thermogram substantially as shown in **Error! Reference source not found.**~~FIG. 3~~.

[Claim 10]. A crystalline anhydrate form of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I):



characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at 16.3, 17.1, 18.7, 19.9, 22.1, or 22.3° 2θ ± 0.2° 2θ, Form A.

~~11. The crystalline form of claim 10, characterized by an XRPD pattern comprising four or more peaks at 16.3, 17.1, 18.7, 19.9, 22.1, or 22.3° 2θ ± 0.2° 2θ.~~

~~12. The crystalline form of claim 10 or 11, characterized by an XRPD pattern comprising five or more peaks at 16.3, 17.1, 18.7, 19.9, 22.1, or 22.3° 2θ ± 0.2° 2θ.~~

~~13. The crystalline form of any one of claims 10 to 12, characterized by an XRPD pattern comprising peaks at 16.3, 17.1, 18.7, 19.9, 22.1, and 22.3° 2θ ± 0.2° 2θ.~~


~~14. The crystalline form of any one of claims 10 to 13, characterized by an XRPD pattern comprising peaks at 9.5, 14.0, 15.5, 16.3, 17.1, 18.5, 18.7, 19.5, 19.9, 21.3, 22.1, 22.3, and 23.3° 2θ ± 0.2° 2θ.~~

~~15. The crystalline form of any one of claims 10 to 14, characterized by an XRPD pattern substantially as shown in FIG. 4.~~

~~16. The crystalline form of any one of claims 10 to 15, characterized by a differential scanning calorimetry (DSC) thermogram having at least one endotherm with an onset of about 250, 251 or 258°C.~~

~~17. The crystalline form of any one of claims 10 to 16, characterized by a DSC thermogram substantially as shown in FIG. 6.~~

[Claim 11~~18~~]. A crystalline anhydrate form of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I):



characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at 17.3, 17.9, 18.3, 18.4, 21.3, or 21.8° 2θ ± 0.2° 2θ, Form C.

~~19. The crystalline form of claim 18, characterized by an XRPD pattern comprising four or more peaks at 17.3, 17.9, 18.3, 18.4, 21.3, or 21.8° 2θ ± 0.2° 2θ.~~

~~20. The crystalline form of claim 18 or 19, characterized by an XRPD pattern comprising five or more peaks at 17.3, 17.9, 18.3, 18.4, 21.3, or 21.8° 2θ ± 0.2° 2θ.~~

~~21. The crystalline form of any one of claims 18 to 20, characterized by an XRPD pattern comprising peaks at 17.3, 17.9, 18.3, 18.4, 21.3, and 21.8° 2θ ± 0.2° 2θ.~~


~~22. The crystalline form of any one of claims 18 to 21, characterized by an XRPD pattern comprising peaks at 8.8, 10.6, 14.3, 15.1, 17.3, 17.7, 17.9, 18.3, 18.4, 19.3, 21.3, 21.8, 22.5, 26.2, and 27.6° 2θ ± 0.2° 2θ.~~

~~23. The crystalline form of any one of claims 18 to 22, characterized by an XRPD pattern substantially as shown in FIG. 7.~~

~~24. The crystalline form of any one of claims 18 to 23, characterized by a differential scanning calorimetry (DSC) thermogram having at least one endotherm with an onset of about 200, 251, 252 or 258°C.~~

~~25. The crystalline form of any one of claims 18 to 24, characterized by a DSC thermogram substantially as shown in FIG. 9.~~

[Claim 112~~26~~]. A crystalline anhydrate form of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I):



characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at 15.9, 16.4, 16.8, 17.3, 19.0, 21.1, or 25.8° 2θ ± 0.2° 2θ, Form F.

~~27. The crystalline form of claim 26, characterized by an XRPD pattern comprising four or more peaks at 15.9, 16.4, 16.8, 17.3, 19.0, 21.1, or 25.8° 2θ ± 0.2° 2θ.~~

~~28. The crystalline form of claim 26 or 27, characterized by an XRPD pattern comprising five or more peaks at 15.9, 16.4, 16.8, 17.3, 19.0, 21.1, or 25.8° 2θ ± 0.2° 2θ.~~

~~29. The crystalline form of any one of claims 26 to 28, characterized by an XRPD pattern comprising peaks at 15.9, 16.4, 16.8, 17.3, 19.0, 21.1, and 25.8° 2θ ± 0.2° 2θ.~~


~~30. The crystalline form of any one of claims 26 to 29, characterized by an XRPD pattern comprising peaks at 9.3, 9.7, 14.1, 14.3, 15.9, 16.4, 16.8, 17.3, 17.8, 19.0, 19.4, 20.4, 20.7, 21.1, 21.5, 22.3, 23.8, 25.1, 25.8, 26.7, 31.2, and 35.3° 2θ ± 0.2° 2θ.~~

~~31. The crystalline form of any one of claims 26 to 30, characterized by an XRPD pattern substantially as shown in FIG. 10.~~

~~32. The crystalline form of any one of claims 26 to 31, characterized by a differential scanning calorimetry (DSC) thermogram having at least one endotherm with an onset of about 257°C.~~

~~33. The crystalline form of any one of claims 26 to 32, characterized by a DSC thermogram substantially as shown in FIG. 12.~~

[Claim 13~~34~~]. A crystalline anhydrate form of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I):



characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at 6.0, 13.1, 17.3, 18.8, 19.8, 20.1, or 21.9° 2θ ± 0.2° 2θ, Form J.

~~35. The crystalline form of claim 34, characterized by an XRPD pattern comprising four or more peaks at 6.0, 13.1, 17.3, 18.8, 19.8, 20.1, or 21.9° 2θ ± 0.2° 2θ.~~

~~36. The crystalline form of claim 34 or 35, characterized by an XRPD pattern comprising five or more peaks at 6.0, 13.1, 17.3, 18.8, 19.8, 20.1, or 21.9° 2θ ± 0.2° 2θ.~~

~~37. The crystalline form of any one of claims 34 to 36, characterized by an XRPD pattern comprising peaks at 6.0, 13.1, 17.3, 18.8, 19.8, 20.1, and 21.9° 2θ ± 0.2° 2θ.~~


~~38. The crystalline form of any one of claims 34 to 37, characterized by an XRPD pattern comprising peaks at 6.0, 13.1, 13.7, 15.6, 17.3, 18.1, 18.3, 18.8, 19.1, 19.8, 20.1, 21.9, 27.4° 2θ ± 0.2° 2θ.~~

~~39. The crystalline form of any one of claims 34 to 38, characterized by an XRPD pattern substantially as shown in FIG. 16.~~

~~40. The crystalline form of any one of claims 34 to 39, characterized by a differential scanning calorimetry (DSC) thermogram having at least one endotherm with an onset of about 247, 251 or 258°C.~~

~~41. The crystalline form of any one of claims 34 to 40, characterized by a DSC thermogram substantially as shown in FIG. 18.~~

[Claim 113~~42~~]. A crystalline anhydrate form of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione (Compound I):



characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at 14.6, 15.5, 19.4, 19.7, or 22.2° 2θ ± 0.2° 2θ, Form L.

~~43. The crystalline form of claim 42, characterized by an XRPD pattern comprising four or more peaks at 14.6, 15.5, 19.4, 19.7, or 22.2° 2θ ± 0.2° 2θ.~~

~~44. The crystalline form of claim 42 or 43, characterized by an XRPD pattern comprising five or more peaks at 14.6, 15.5, 19.4, 19.7, or 22.2° 2θ ± 0.2° 2θ.~~

~~45. The crystalline form of any one of claims 42 to 44, characterized by an XRPD pattern comprising peaks at 14.6, 15.5, 19.4, 19.7, and 22.2° 2θ ± 0.2° 2θ.~~


~~46. The crystalline form of any one of claims 42 to 45, characterized by an XRPD pattern comprising peaks at 13.1, 13.6, 14.6, 15.5, 17.2, 18.6, 19.4, 19.7, 20.6, 21.7, 22.2, 23.2, 24.5, 26.1, 27.5, and 28.6° 2θ ± 0.2° 2θ.~~

~~47. The crystalline form of any one of claims 42 to 46, characterized by an XRPD pattern substantially as shown in FIG. 22.~~

~~48. The crystalline form of any one of claims 42 to 47, characterized by a differential scanning calorimetry (DSC) thermogram having at least one endotherm with an onset of about 257°C.~~

~~49. The crystalline form of any one of claims 42 to 48, characterized by a DSC thermogram substantially as shown in FIG. 24.~~

Claim 114~~50~~]. A crystalline form of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione THF solvate (Compound I, THF solvate):



characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at 17.2, 18.9, 20.9, 23.5, 25.0, or 25.6° 2θ ± 0.2° 2θ, THF solvate Form H.

~~51. The crystalline form of claim 50, characterized by an XRPD pattern comprising four or more peaks at 17.2, 18.9, 20.9, 23.5, 25.0, or 25.6° 2θ ± 0.2° 2θ.~~

~~52. The crystalline form of claim 50 or 51, characterized by an XRPD pattern comprising five or more peaks at 17.2, 18.9, 20.9, 23.5, 25.0, or 25.6° 2θ ± 0.2° 2θ.~~

~~53. The crystalline form of any one of claims 50 to 52, characterized by an XRPD pattern comprising peaks at 17.2, 18.9, 20.9, 23.5, 25.0, and 25.6° 2θ ± 0.2° 2θ.~~


~~54. The crystalline form of any one of claims 50 to 53, characterized by an XRPD pattern comprising peaks at 7.9, 11.0, 12.0, 12.4, 13.0, 15.7, 17.0, 17.1, 17.2, 18.9, 19.1, 20.4, 20.6, 20.9, 23.5, 25.0, and 25.6° 2θ ± 0.2° 2θ.~~

~~55. The crystalline form of any one of claims 50 to 54, characterized by an XRPD pattern substantially as shown in FIG. 13.~~

~~56. The crystalline form of any one of claims 50 to 55, characterized by a differential scanning calorimetry (DSC) thermogram having at least one endotherm with an onset of about 254°C.~~

~~57. The crystalline form of any one of claims 50 to 56, characterized by a DSC thermogram substantially as shown in FIG. 15.~~

[Claim 16~~58~~]. A crystalline form of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione acetic acid (Compound I, acetic acid solvate):



characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at 16.0, 16.8, 19.4, 22.3, 23.6, or 26.9° 2θ ± 0.2° 2θ, AcOH solvate Form K.

~~59. The crystalline form of claim 58, characterized by an XRPD pattern comprising four or more peaks at 16.0, 16.8, 19.4, 22.3, 23.6, or 26.9° 2θ ± 0.2° 2θ.~~

~~60. The crystalline form of claim 58 or 59, characterized by an XRPD pattern comprising five or more peaks at 16.0, 16.8, 19.4, 22.3, 23.6, or 26.9° 2θ ± 0.2° 2θ.~~

~~61. The crystalline form of any one of claims 58 to 60, characterized by an XRPD pattern comprising peaks at 16.0, 16.8, 19.4, 22.3, 23.6, and 26.9° 2θ ± 0.2° 2θ.~~


~~62. The crystalline form of any one of claims 58 to 61, characterized by an XRPD pattern comprising peaks at 7.3, 8.4, 10.8, 11.0, 13.0, 15.2, 16.0, 16.7, 16.8, 18.5, 19.0, 19.1, 19.3, 19.4, 19.9, 20.3, 22.0, 22.3, 23.1, 23.6, 24.0, 24.1, 25.2, 25.6, 26.2, 26.9, 27.7, 29.1, 30.0, and 33.7° 2θ ± 0.2° 2θ.~~

~~63. The crystalline form of any one of claims 58 to 62, characterized by an XRPD pattern substantially as shown in FIG. 19.~~

~~64. The crystalline form of any one of claims 58 to 63, characterized by a differential scanning calorimetry (DSC) thermogram having at least one endotherm with an onset of about 106 or 254°C.~~

~~65. The crystalline form of any one of claims 58 to 64, characterized by a DSC thermogram substantially as shown in FIG. 21.~~

[Claim 17~~66~~]. A crystalline form of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione dioxane (Compound I, dioxane solvate):



characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at 15.3, 17.5, 19.5, 20.1, 20.7, or 26.8° 2θ ± 0.2° 2θ, Dioxane solvate Form M.

~~67. The crystalline form of claim 66, characterized by an XRPD pattern comprising four or more peaks at 15.3, 17.5, 19.5, 20.1, 20.7, or 26.8° 2θ ± 0.2° 2θ.~~

~~68. The crystalline form of claim 66 or 67, characterized by an XRPD pattern comprising five or more peaks at 15.3, 17.5, 19.5, 20.1, 20.7, or 26.8° 2θ ± 0.2° 2θ.~~

~~69. The crystalline form of any one of claims 66 to 68, characterized by an XRPD pattern comprising peaks at 15.3, 17.5, 19.5, 20.1, 20.7, and 26.8° 2θ ± 0.2° 2θ.~~


~~70. The crystalline form of any one of claims 66 to 69, characterized by an XRPD pattern comprising peaks at 10.7, 14.5, 15.3, 16.2, 17.5, 18.8, 19.1, 19.5, 19.8, 20.1, 20.4, 20.7, 21.5, 22.3, 22.5, 25.1, 26.8, 26.9, 28.7, 29.5, and 38.0° 2θ ± 0.2° 2θ.~~

~~71. The crystalline form of any one of claims 66 to 70, characterized by an XRPD pattern substantially as shown in FIG. 25.~~

~~72. The crystalline form of any one of claims 66 to 71, characterized by a differential scanning calorimetry (DSC) thermogram having at least one endotherm with an onset of about 254°C.~~

~~73. The crystalline form of any one of claims 66 to 72, characterized by a DSC thermogram substantially as shown in FIG. 27.~~

[Claim 18~~74~~]. A crystalline form of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione acetone (Compound I, acetone solvate):



characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at 15.9, 17.0, 17.2, 17.5, 18.8, 20.6, or 25.4° 2θ ± 0.2° 2θ, Acetone solvate Form Q.

~~75. The crystalline form of claim 74, characterized by an XRPD pattern comprising four or more peaks at 15.9, 17.0, 17.2, 17.5, 18.8, 20.6, or 25.4° 2θ ± 0.2° 2θ.~~


~~76. The crystalline form of claim 74 or 75, characterized by an XRPD pattern comprising five or more peaks at 15.9, 17.0, 17.2, 17.5, 18.8, 20.6, or 25.4° 2θ ± 0.2° 2θ.~~

~~77. The crystalline form of any one of claims 74 to 76, characterized by an XRPD pattern comprising peaks at 15.9, 17.0, 17.2, 17.5, 18.8, 20.6, and 25.4° 2θ ± 0.2° 2θ.~~

~~78. The crystalline form of any one of claims 74 to 77, characterized by an XRPD pattern comprising peaks at 7.8, 10.0, 11.0, 11.8, 12.0, 12.8, 15.9, 17.0, 17.2, 17.5, 18.8, 19.3, 20.1, 20.3, 20.6, 22.1, 22.5, 23.0, 24.0, 25.2, 25.4, 25.9, 26.4, 26.8, 27.2, 27.9, 30.2, 31.1, and 35.6° 2θ ± 0.2° 2θ.~~

~~79. The crystalline form of any one of claims 74 to 78, characterized by an XRPD pattern substantially as shown in FIG. 28.~~

[Claim 19~~80~~]. A crystalline form of (E)-6-(4-Phenylcyclohexyl)-5-(3-trifluoromethylbenzyl)-1H-pyrimidine-2,4-dione methanol (Compound I, methanol solvate):



MeOH

characterized by an X-ray powder diffraction (XRPD) pattern comprising three or more peaks at 10.6, 14.6, 20.3, 20.4, or 23.3° 2θ ± 0.2° 2θ, MeOH solvate Form R.

~~81. The crystalline form of claim 80, characterized by an XRPD pattern comprising four or more peaks at 10.6, 14.6, 20.3, 20.4, or 23.3° 2θ ± 0.2° 2θ.~~

~~82. The crystalline form of claim 80 or 81, characterized by an XRPD pattern comprising peaks at 10.6, 14.6, 20.3, 20.4, and 23.3° 2θ ± 0.2° 2θ.~~

~~83. The crystalline form of any one of claims 80 to 82, characterized by an XRPD pattern comprising peaks at 6.8, 10.6, 11.8, 12.6, 13.4, 14.6, 17.7, 18.2, 20.0, 20.3, 20.4, 22.0, 22.2, 22.4, 23.3, 24.3, 26.4, 27.1, 27.2, 30.9, and 39.3° 2θ ± 0.2° 2θ.~~

~~84. The crystalline form of any one of claims 80 to 83, characterized by an XRPD pattern substantially as shown in FIG. 30.~~

~~85. The crystalline form of any one of claims 80 to 84, characterized by a differential scanning calorimetry (DSC) thermogram having at least one endotherm with an onset of about 72, 186, 248, 252 or 257°C.~~

~~86. The crystalline form of any one of claims 80 to 85, characterized by a DSC thermogram substantially as shown in FIG. 32.~~

[Claim 20~~87~~]. A pharmaceutical composition comprising a crystalline form of any one of claims 1 to ~~86~~19, and one or more pharmaceutically acceptable excipients.

[Claim 21~~88~~]. The pharmaceutical composition of claim ~~87~~20, further comprising one or more additional therapeutic agents.

[Claim 2289]. A method of treating a disorder or condition through modulating a glucocorticoid receptor, comprising administering to a subject in need of such treatment, a therapeutically effective amount ofA a crystalline form of any one of claims 1 to 8619, or a pharmaceutical composition of claims 87 20 or 8821, for use in thereby treating the a disorder or condition through modulating a glucocorticoid receptor.

[Claim 2390]. A method of treating a disorder or condition through antagonizing a glucocorticoid receptor, comprising administering to a subject in need of such treatment, a therapeutically effective amount of a crystalline form of any one of claims 1 to 8619, or a pharmaceutical composition of claims 87 20 or 8821, for use in thereby treating the a disorder or condition through antagonizing a glucocorticoid receptor.

[Claim 2491]. Use of a crystalline form A method of treating fatty liver disease, comprising administering to a subject in need thereof, a therapeutically effective amount of a composition of any one of claims 1 to 8619, or a pharmaceutical composition of claims 87 20 or 8821, in the preparation of a medicament for use inthereby treating fatty liver disease.

[Claim 2592]. The method use of claim 9124, wherein the fatty liver disease is alcohol related liver disease (ARLD) or nonalcoholic fatty liver disease (NAFLD).

[Claim 9326]. The method use of claim 9225, wherein the alcohol related liver disease is alcohol fatty liver disease (AFL), alcoholic steatohepatitis (ASH) or alcoholic cirrhosis.

[Claim 2794]. The method use of claims 91 25or 92, wherein the nonalcoholic fatty liver disease is nonalcoholic steatohepatitis (NASH) or nonalcoholic cirrhosis.

[Claim 2895]. The method use of claim 9425 or 27, wherein the nonalcoholic fatty liver disease is nonalcoholic steatohepatitis.

[Claim 2996]. A method of treating antipsychotic induced weight gain, comprising administering to a subject in need thereof, a therapeutically effective amountUse of the crystalline form of any one of claims 1 to 8619, or a pharmaceutical composition of claims 87 20 or 8821, in the preparation of a medicament forthereby treating antipsychotic induced weight gain.